- Home
- MRM vs MYNZ Comparison
MRM vs MYNZ Comparison
Compare MRM & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- MYNZ
- Stock Information
- Founded
- MRM 2000
- MYNZ 2021
- Country
- MRM Japan
- MYNZ Germany
- Employees
- MRM N/A
- MYNZ N/A
- Industry
- MRM Other Consumer Services
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- MYNZ Health Care
- Exchange
- MRM Nasdaq
- MYNZ Nasdaq
- Market Cap
- MRM 5.9M
- MYNZ 5.5M
- IPO Year
- MRM 2020
- MYNZ 2021
- Fundamental
- Price
- MRM $1.36
- MYNZ $1.37
- Analyst Decision
- MRM
- MYNZ Buy
- Analyst Count
- MRM 0
- MYNZ 2
- Target Price
- MRM N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- MRM 44.6K
- MYNZ 118.7K
- Earning Date
- MRM 05-20-2025
- MYNZ 07-07-2025
- Dividend Yield
- MRM N/A
- MYNZ N/A
- EPS Growth
- MRM 27.65
- MYNZ N/A
- EPS
- MRM 0.18
- MYNZ N/A
- Revenue
- MRM $52,786,758.00
- MYNZ $893,991.00
- Revenue This Year
- MRM N/A
- MYNZ $26.06
- Revenue Next Year
- MRM N/A
- MYNZ $4.97
- P/E Ratio
- MRM $8.41
- MYNZ N/A
- Revenue Growth
- MRM 21.55
- MYNZ N/A
- 52 Week Low
- MRM $0.34
- MYNZ $1.34
- 52 Week High
- MRM $8.39
- MYNZ $22.40
- Technical
- Relative Strength Index (RSI)
- MRM 49.70
- MYNZ 23.25
- Support Level
- MRM $1.32
- MYNZ $1.34
- Resistance Level
- MRM $1.50
- MYNZ $1.48
- Average True Range (ATR)
- MRM 0.09
- MYNZ 0.13
- MACD
- MRM -0.05
- MYNZ -0.01
- Stochastic Oscillator
- MRM 18.92
- MYNZ 3.72
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.